Fate Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Fate Therapeutics

28/02/2022 22:41

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly
adjusted
loss of 72 cents​​ per share for the quarter ended in December.
The mean expectation of nineteen analysts for the quarter was
for a loss of 67 cents per share.
    * Revenue rose 7.4% to $17.07 million from a year ago; 
analysts
expected $10.73 million. 
    * Fate Therapeutics Inc's reported EPS for the quarter was a
loss
of 72 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.4%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Fate Therapeutics Inc shares had fallen by 40.3% this
quarter.
    * The company reported a quarterly loss of $68.62 million.
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $109.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 16 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated February 28 at 10:41 p.m.
 ​All figures in US dollars unless otherwise stated